monepantel oral liquid (NUZ-001 oral liquid) / Neurizon Therapeutics - LARVOL DELTA

Neurizon received approval for a Phase 1 trial of liquid NUZ-001 for ALS in Australia. (ALS News Today) - "'The Bellberry Human Research Ethics Committee, an independent Australian ethics review board that oversees research involving human participants, approved the company’s plan for the trial, which will compare the liquid formulation with the tablet version in 32 healthy volunteers...The four-arm trial will assess the safety and pharmacological properties of the two formulations when taken in a fasting state or after a meal. It also aims to evaluate changes in ALS biomarkers and the palatability of the liquid formulation to support its continued development. The study will start in the third quarter of 2026 and conclude by the end of the year.'"

New P1 trial • Trial completion date • Trial initiation date • Amyotrophic Lateral Sclerosis